key: cord-0796240-ah57x7ty
authors: Schernthaner, Guntram
title: Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
date: 2021-07-30
journal: Diabetes Metab J
DOI: 10.4093/dmj.2021.0081
sha: 6bf329156c15ca1f8fed2ec66ec86a409fabea5d
doc_id: 796240
cord_uid: ah57x7ty

nan

People with diabetes are at increased risk of severe coronavirus disease 2019 (COVID-19) complications, and COVID-19-related mortality in this population is two to three times higher than that in people without diabetes [1] . Glucose-lowering drugs used in the treatment of patients with diabetes might have significant effects on COVID-19 pathophysiology, potentially affecting the risk of progression to severe disease and mortality. Rhee et al. [2] reported data suggesting that dipeptidyl peptidase-4 inhibitors (DPP-4is) are significantly associated with a better clinical outcome in patients with COVID-19. The unadjusted odds ratio (OR) of severe/lethal cases among DPP-4i users was 0.77 (95% confidence interval [CI], 0.35 to 1.68); after some adjustment, the OR changed to 0.36 (95% CI, 0.13 to 0.97). This enourmous discrepancy-between the unadjusted and adjusted ORs-is difficult to understand.

The authors have compared relatively small cohorts not matched for critical factors. While DPP-4i users (n=263) and non-DPP-4i users (n=569) had a similar baseline risk for some mortality-linked comorbidities (e.g., cardiovascular disease, 26% vs. 28%; chronic kidney disease, 16% vs. 11%; and cancer, 18% vs. 24%), no information was given about heart failure, which is now one of the leading risk factors for mortality in diabetic patients. By contrast, treatment quality was extremely different and significantly better in the group receiving DPP-4i compared with non-users (metformin, 82% vs. 15%; statins, 61% vs. 29%; renin-angiotensin system blockade, 49% vs. 24%; and angiotensin receptor blocker inhibitors, 47% vs. 23%).

Thus, it is extremely likely that the use of metformin and cardioprotective drugs have strongly influenced relative clinical outcomes for patients using DPP-4i. Indeed, a recent meta-analysis [3] of five studies encompassing 8,121 patients with diabetes who were admitted to hospital for COVID-19 showed a significantly reduced mortality rate associated with the use of metformin (OR, 0.62; 95% CI, 0.43 to 0.89). In addition, a recent population-based cohort study from Korea [4] showed that the use of statins was associated with lower mortality in patients with COVID-19 (hazard ratio [HR], 0.64; 95% CI, 0.42 to 0.95).

Very recently, several large population studies were published analyzing the effect of different glucose-lowering drugs on mortality in patients with diabetes during the COVID-19 pandemic (Table 1 ). In the UK, the pre-infection prescription of glucose-lowering therapies and risk of COVID-19 mortality was analysed in 2.85 million people with type 2 diabetes mellitus [5] . Overall, a COVID-19-related death occurred in 13,479 (0.5%) subjects. Metformin, sodium glucose co-transporter 2 (SGLT2) inhibitors, and sulfonylureas were associated with reduced risks of COVID-19-related mortality, whereas insulin and DPP-4is were associated with increases in risk; neutral results were found for glucagon-like peptide-1 (GLP-1) receptor agonists and thiazolidinediones. Interestingly, the use of SGLT2 inhibitors (HR, 0.82; 95% CI, 0.74 to 0.91) compared with DPP-4is (HR, 1.07; 95% CI, 1.01 to 1.13) was associated with significantly lower COVID-19 mortality risk [2] . However, as expected from treatment recommendations [6, 7] , pa- tients using DPP-4i in the UK study were older and were more likely to have chronic kidney disease [5] .

In a Danish population-based study [8] , the impact of current use of novel glucose-lowering drugs on COVID-19 was studied and relative risks (RR) were calculated after applying propensity score weighted methods to control for confounding. Current users of GLP-1 receptor agonists had an adjusted RR of 0.89 (95% CI, 0.34 to 2.33), while users of DPP-4i had an adjusted RR of 2.42 (95% CI, 0.99 to 5.89), for 30-day mortality compared with SGLT2 inhibitor use. In the French population-based Coronavirus SARS-CoV-2 and Diabetes Outcomes (CORONADO) study [9] , the use of metformin was associated with a significantly reduced mortality in diabetic patients with COVID-19 (OR, 0.63; 95% CI, 0.52 to 0.77), whereas the use of DPP-4i had a neutral effect (OR, 0.83; 95% CI, 0.65 to 1.05). In a recent meta-analysis of seven studies [10] , death occurred in 111 of 612 (18%) patients treated with DPP-4i and in 335 of 1,703 (20%) patients treated with other glucose-lowering medication, again suggesting a neutral effect (RR, 0.81; 95% CI, 0.57 to 1.15).

Several randomized controlled trials (NCT04365517, NCT04371978, and NCT04341935) are being conducted with DPP-4is in patients with type 2 diabetes mellitus and COV-ID-19. Until we have evidence from prospective, randomized studies such as these, data on the effectiveness or safety of DPP-4i in patients with COVID-19 should be interpreted with caution.

No potential conflict of interest relevant to this article was reported.

Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?

Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19

Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis

Beneficial effect of statins in COVID-19-related outcomes-brief report: a national population-based cohort study

Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease

Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

Table 1. Effect of DPP-4is on COVID-19 related mortality/severe outcome in population based studies